Gene Therapy and Exudative Age Related Macular Degeneration
Tracy Doll, OD
Expires December 1, 2010
1 credits, $39
Section: Retina and Posterior Segment
Age Related Macular Degeneration (ARMD) is the leading cause of blindness in Industrialized Nations. Currently 1.8 million Americans over the age of 40 are affected with advanced age related macular degeneration. This number is projected to grow to 2.9 million by the year 2020.
Prevent Blindness America released a report this April estimating the cost of adult related vision related disorders (including age-related macular degeneration, cataract, diabetic retinopathy, primary open-angle glaucoma, refractive error, visual impairment and blindness) at $51.4 billion. An estimated $575 million is spent solely on ARMD costs.
New potential methods of ARMD treatment and management are currently being researched in hopes to lessen the impact ARMD has on our society.